靶向治疗药物联合放化疗治疗肺癌脑转移临床评价  

作　　者：姚满田[1] 江冠铭[1] 刘淳[1] 

机构地区：[1]广东省东莞市人民医院肿瘤内科,广东东莞523000

出　　处：《中国药业》2020年第S02期14-15,共2页China Pharmaceuticals

摘　　要：目的探讨靶向治疗药物联合放化疗治疗肺癌脑转移的临床疗效。方法选取医院2018年1月至2019年3月收治的肺癌脑转移患者80例,采用随机单盲法分为对照组与观察组,各40例。对照组患者予放化疗治疗,观察组患者予靶向治疗药物联合放化疗治疗,比较两组临床疗效。结果观察组总有效率为87.50%,明显高于对照组的62.50%(P<0.05);观察组患者无进展生存期和总生存期明显长于对照组(P<0.05)。结论靶向治疗药物联合放化疗治疗肺癌脑转移临床疗效显著,可延长患者生存时间,减少不良反应。Objective To investigate the clinical efficacy of targeted therapeutic drugs combined with chemoradiotherapy in the treatment of patients with brain metastasis from lung cancer.Methods Totally 80 patients with brain metastasis from lung cancer admitted to our hospital from January 2018 to March 2019 were selected and randomly divided into the control group and the observation group,40 cases in each group.The patients in the control group were treated with radiotherapy and chemotherapy,while the patients in the observation group were treated with targeted drugs combined with radiotherapy and chemotherapy.Results The total effective rate of the observation group was 87.50%,which was significantly higher than 62.50%of the control group(P<0.05),the progression free survival and overall survival of the observation group were significantly longer than those of the control group(P<0.05).Conclusion Targeted therapy combined with radiotherapy and chemotherapy is effective in the treatment of brain metastasis of lung cancer,which can prolong the survival time of patients and reduce adverse reactions.

关 键 词：靶向治疗药物 放化疗 肺癌脑转移 临床疗效 无进展生存期 总生存期 

分 类 号：R979.1[医药卫生—药品]